Ping Cao, BridGene CEO
BridGene nets another Takeda deal amid plans to raise more funding and go public
Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences.
The Tokyo-based drugmaker announced Tuesday that it is once again …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
